COVID-19 long haulers

With the risks of drug development prohibitive, repurposed or repositioned medicines appear the best hope against long-COVID, a condition that still raises many unanswered questions.

July 2021 sw_admin 0

Phage Therapy’s Latest Makeover

As issues of product consistency, standardization and specificity are being tackled, can phage therapeutics—long oversold and overhyped—finally realize their antibacterial potential?

April 2019 sw_admin 0

Inflammation and Brain Health

Normally a guard against brain injury and infection, inflammation is increasingly being implicated in cognitive decline

September 2021 sw_admin 0

The Virome Hunters

Ambitious efforts to catalog viruses across the globe may facilitate our understanding of viral communities and ecology, boost infectious disease diagnostics and surveillance, and spur new therapeutics.

October 2018 sw_admin 0

First Deuterated Drug Approved

In April, the US Food and Drug Administration cleared the first deuterated drug, Austedo (deutetrabenazine), from Teva of Petach Tikva, Israel, for the treatment of Huntington’sdisease-related movement disorders.

June 2017 sw_admin 0